近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Venkataraman, N., Cole, A.L.*, Svoboda, P., Pohl, J, Cole, A.M. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 175(11): 7560-7, 2005
Cole, A.L., Yang, O.O., Warren, A.D., Waring, A.J., Lehrer, R.I., Cole, A.M. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J. Immunol. 176(11): 6900-5, 2006
Cole, A.L., Herasimtschuk, A., Gupta, P., Waring, A.J., Lehrer, R.I., and Cole, A.M. The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct. Immunology 121(1): 140-5, 2007
Keller M.J., Guzman, E., Hazrati, E., Kasowitz, A., Cheshenko, N., Wallenstein, S., Cole, A.L., Cole, A.M., Profy, A.T., Wira, C.R., Hogarty, K., Herold, B.C. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 21(4): 467-476, 2007
Fuhrman, C.A., Warren, A.D., Waring, A.J., Dutz, S.M., Sharma, S., Lehrer, R.I., Cole, A.L., and Cole, A.M. Retrocyclin (RC)-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41. FEBS J. 274(24): 6477-87, 2007
Cole, A.M., Cole, A.L. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am. J. Reprod. Immunol. 59(1): 27-34, 2008
Martellini, J.A., Cole, A.L., Venkataraman, N., Quinn, G.A., Svoboda, P., Gangrade, B.K., Pohl, J., Sorensen, O.E., Cole, A.M. Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma. FASEB J. 23(10): 3609-18, 2009
Cole, A.M., Patton, D.L., Rohan, L.C., Cole, A.L., Cosgrove-Sweeney, Y., Rogers, N.A., Ratner, D., Sassi, A., Tarwater, P., Ramratnam, B., Ruchala, P., Lehrer, R.I., Waring, A.J., and Gupta, P. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS ONE 5(11): e15111, 2010.
Sassi, A.B., Cost, M.R., Cole, A.L., Cole, A.M., Patton, D.L., Gupta, P., and Rohan, L.C. Formulation development of Retrocyclin-1 (RC-101) as an anti-HIV vaginal microbicide product. Antimicrob Agents and Chemother 55(5): 2282-9, 2011
Martellini, J.A., Cole, A.L., Svoboda, P., Stuchlik, O., Chen, L.M., Chai, K.X., Gangrade, B.K., Sorensen, O.E., Pohl, J., and Cole, A.M. HIV-1 enhancing effect of prostatic acid phosphatase peptides is reduced in human seminal plasma. PLoS ONE 6(1): e16285, 2011.
Ruchala, P., Cho, S., Cole, A.L., Carpenter, C., Jung, C-L., Luong, H., Micewicz, E.D., Waring, A.J., Cole, A.M., Herold, B.C., Lehrer, R.I. Simplified theta-defensins: search for new antivirals. Int. J. Peptide Res. and Ther. Published online Sept 23, 2011
Levinson, P., Choi, R.Y., Cole, A.L., Hirbod, T., Rhedin, S., Payne, B., Guthrie, B.L., Bosire, R., Cole, A.M., Farquhar, C., Broliden, K. HIV-Neutralizing Activity of Cationic Polypeptides in Cervicovaginal Secretions of Women in HIV-Serodiscordant Relationships. PLoS One 2012; 7(2):e31996. Epub 2012 Feb 28
Eade, C.R., Diaz, C., Wood, M.P., Anastos, K., Patterson, B.K., Gupta, P., Cole, A.L., Cole, A.M. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLOS One. 7(11): 250106 Epub 2012 Nov15
Eade, C.R., Cole, A.L.*, Diaz, C., Rohan, L.C., Parniak, M.A., Marx, P., Tarwater, P.M., Gupta, P., Cole, A.M. The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa. Amer J Rep Immunol. 69(2): 150-8, 2013
Wood, M.P., Cole, A.L., Ruchala, P., Waring, A.J., Rohan, L.C., Marx, P., Tarwater, P.M., Gupta, P., Cole, A.M. A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. PLOS One. 8(2):e55478 Epub 2013 Feb5
Wood. M.P., Cole, A.L., Eade, C.R., Chen, LM, Chai, K.X., Cole, A.M. The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2. Accepted to Immunology, March 6, 2014